Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on novel therapies for glaucoma, corneal disorders, and retinal diseases. Headquartered in Aliso Viejo, California, the company has built a leadership position in micro-invasive glaucoma surgery (MIGS) through products such as iStent, iStent inject, iStent infinite, and the PRESERFLO MicroShunt. Its flagship growth driver is iDose TR, a sustained-release travoprost implant designed to lower intraocular pressure in patients with glaucoma or ocular hypertension, while its corneal health franchise is anchored by Photrexa and the newly launched Epioxa. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow the stock closely because of its expanding commercial infrastructure, differentiated technology platforms, and a pipeline spanning glaucoma, corneal health, and retinal disease.
Over the last 30 days, Glaukos shares advanced approximately 14.4%, rising from a closing price of $158.56 on September 28, 2026, to $181.47 by October 28, 2026. The move was not a straight line: shares dipped near $153 in late September, rallied toward $172 in early October, pulled back sharply on October 8 following the Epioxa Phase 3 extension data announcement, and then recovered into the high $170s and low $180s ahead of the company's third-quarter report. The longer-term trend is even stronger. Over the trailing quarter, the stock climbed roughly 19.9%, from about $151.33 in late July to $181.47, driven primarily by a well-received second-quarter earnings report and a series of raised revenue forecasts. The shares have traded near the upper end of a wide 52-week range that spans from a low near $76.88 to a high of $191.62.
The recent advance reflects continued investor confidence in Glaukos' two transformational growth engines. iDose TR generated approximately $74 million in sales during the second quarter, and management has highlighted growing surgeon adoption, increasing utilization, and expanding payer access. The Epioxa launch has also progressed, with a product-specific J-code (J2789) effective July 1, 2026, and market-access pathways established for more than 125 million covered commercial lives in the U.S. The 30-day window also included a notable bout of volatility. In early October, Glaukos announced positive three-year Phase 3 extension data for Epioxa demonstrating sustained effectiveness and safety; despite the favorable data, the stock fell more than 13% in a single session as investors weighed valuation and launch-related expectations. Shares subsequently rebounded as analysts reiterated a broadly bullish stance on the stock and as momentum building toward the third-quarter report outweighed near-term concerns.
The quarterly gain of roughly 19.9% is anchored by Glaukos' second-quarter 2026 results, reported on July 29. The company posted record consolidated net sales of $185.6 million, up 50% year over year, and an adjusted loss of $0.14 per share that was narrower than consensus expectations. U.S. glaucoma revenue rose 64% to a record $118.5 million, while corneal health revenue climbed 48% to $30.4 million, including approximately $11 million from Epioxa. Management raised its full-year 2026 net sales guidance to a range of $680 million to $700 million, up from $620 million to $635 million previously. The combination of accelerating revenue, improving gross margins, and narrowing operating losses reinforced the narrative that Glaukos is transitioning toward sustained growth and eventual profitability, supporting the stock's multi-month uptrend.
Several factors are likely to shape Glaukos' trajectory in the months ahead. The pace of iDose TR adoption and utilization remains the central growth driver, along with the continued commercial ramp of Epioxa and the expansion of its site-of-care network. Reimbursement developments also carry weight: five of the seven Medicare administrative contractors have issued proposed local coverage determinations for iDose TR, and the final outcomes could influence near-term volume trends. Investors will also monitor guidance updates, gross-margin trajectory, and progress toward narrowing operating losses as the company scales. Competitive dynamics in MIGS globally, foreign-exchange effects, and broader macroeconomic conditions affecting elective ophthalmic procedures round out the list of variables to watch. As with any growth-stage medical technology company, execution on launch milestones and payer access will be critical to sustaining the recent momentum.
In my research process, I often review Tickeron’s Trending AI Robots to get a curated view of automated strategies across hundreds of tickers. The platform highlights top-performing bots with varying timeframes and risk profiles, which can offer useful perspective on how systematic approaches are positioned relative to manual analysis. This helps round out my own assessment without replacing core fundamental review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GKOS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 46 similar instances where the stock broke above the upper band. In 34 of the 46 cases the stock fell afterwards. This puts the odds of success at 74%.
The 10-day RSI Indicator for GKOS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 27 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 71 cases where GKOS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 61%.
The Moving Average Convergence Divergence Histogram (MACD) for GKOS turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In 41 of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on GKOS as a result. In 82 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +8.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 232 of 314 cases where GKOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.395) is normal, around the industry mean (4.142). P/E Ratio (-68.627) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an ophthalmic medical device company
Industry MedicalNursingServices